Regeneron receives Eu Ok for new use of Eylea

The Tarrytown, N.Y., company said Thursday that the European Commission cleared the drug for use in the European Union to treat visual impairment from macular edema following central retinal vein occlusion, a condition for which the drug already has received approval in the United States.

http://www.miamiherald.com/2013/08/29/3593256/regeneron-receives-eu-ok-for-new.html